I
Ignace Demeyer
Publications - 5
Citations - 1499
Ignace Demeyer is an academic researcher. The author has contributed to research in topics: Placebo & Intensive care. The author has an hindex of 5, co-authored 5 publications receiving 1412 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.
Edward Abraham,Konrad Reinhart,Steven M. Opal,Ignace Demeyer,Christopher J. Doig,Angel López Rodriguez,Richard Beale,Petr Svoboda,Pierre-François Laterre,Stuart Simon,Bruce Light,Herbert Spapen,Judy Stone,Allan Seibert,Claus Peckelsen,Cathy De Deyne,Russell Postier,Ville Pettilä,Charles L. Sprung,Antonio Artigas,Sandra Percell,Vincent Shu,Christian Zwingelstein,Jeffrey Tobias,Lona Poole,James C. Stolzenbach,Abla A. Creasey +26 more
TL;DR: Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR and tifACogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis
Todd W. Rice,Arthur P. Wheeler,Gordon R. Bernard,Jean Louis Vincent,Derek C. Angus,Naoki Aikawa,Ignace Demeyer,Stephen Sainati,Nicholas Amlot,Charlie Cao,Masayuki Ii,Hideyasu Matsuda,Kouji Mouri,Jonathan Cohen +13 more
TL;DR: TAK-242 failed to suppress cytokine levels in patients with sepsis and shock or respiratory failure, and treatment with TAK-242 resulted in mild increases in serum methemoglobin levels but was otherwise well tolerated.
Journal ArticleDOI
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial
Steven M. Opal,Pierre-François Laterre,Edward Abraham,Bruno François,Xavier Wittebole,Stephen F. Lowry,Jean-François Dhainaut,Brian Warren,Thierry Dugernier,Ángel Juan Gordo López,Miguel Angel Gomez Sanchez,Ignace Demeyer,Luis Jauregui,José A. Lorente,William T. McGee,Konrad Reinhart,Sascha Kljucar,Sonia Souza,John Pribble +18 more
TL;DR: rPAF-AH was well tolerated and not antigenic, but did not decrease 28-day all-cause mortality in patients with severe sepsis, and no rPAf-AH-treated patients developed antibodies to PAF- AH.
Journal ArticleDOI
The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial.
Andreas Seekamp,Martijn van Griensven,Erwin Dhondt,M. Diefenbeck,Ignace Demeyer,Guy Vundelinckx,Norbert P. Haas,Ulrich Schaechinger,Laura Wolowicka,Stefan Rammelt,Jan Stroobants,Ingo Marzi,Ansgar M. Brambrink,Piotr Dziurdzik,Jacek Gasiorowski,Heinz Redl,Michael Beckert,Jasmin Khan-Boluki +17 more
TL;DR: Aselizumab was associated with a higher rate of infections and leucopenia; however, this difference was not significantly different compared with placebo, and for all efficacy variables, aselIZumab presented no significant trends but only a few scattered statistically significant differences between groups.
Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
Edward Abraham,Steven M. Opal,Ignace Demeyer,Richard Beale,Petr Svoboda,Stuart Simon,Bruce Light,Judy Stone,Claus Peckelsen,Cathy De Deyne,Ville Pettilä,Charles L. Sprung,Sandra Percell,Vincent Shu,Lona Poole,James C. Stolzenbach,Abla A. Creasey +16 more
TL;DR: The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis and TFPI forms a complex with tissue factor and blood protease factors leading to inhibition of thrombin generation and fibrin formation.